An algorithm to identify patients with rare genetic disorders and its real-world data application

- 5 Bryn D. Webb, MD^{1,2*}; Lisa Y. Lau, PhD, MPH^{1*}; Despina Tsevdos, MD³; Ryan A. Shewcraft,
- 6 PhD¹; David Corrigan, PhD¹; Lisong Shi, PhD¹; Seungwoo Lee, MS¹; Jonathan Tyler, PhD¹;
- 7 Shilong Li, PhD¹; Zichen Wang, PhD¹; Gustavo Stolovitzky, PhD¹; Lisa Edelmann, PhD¹; Rong
- 8 Chen, PhD¹; Eric E. Schadt, PhD^{1,4†}; Li Li, MD, MS^{1†}
- 10 ¹GeneDx, Stamford, CT, USA.
- ²Department of Pediatrics, University of Wisconsin School of Medicine and Public Health,
- 12 Madison, WI, USA

1

2

3 4

9

16 17

19 20

252627

28 29

32 33

38

- ³Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- ⁴Department of Genetics and Genomic Sciences, The Icahn Institute for Genomics and
- 15 Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
 - *Contributed equally as co-first authors
- 18 ** Contributed equally as co-senior authors; corresponding authors
 - Corresponding authors' details
- 21 Name: Li Li
- 22 Address: 333 Ludlow St, Stamford, Connecticut 06902, USA
- Telephone: 475-533-3720
 Email: li.li@sema4.com
 - **Short Title**: Identifying patients with rare genetic disorders
- Conflict of Interest Disclosures: The authors have no conflicts of interest relevant to this article to disclose.
- Funding/Support: None. This project was performed in collaboration with GeneDx. GeneDx is a company that integrates genetic testing and data analytics to improve diagnosis, treatment, and prevention of disease. The Icahn School of Medicine at Mount Sinai holds equity in this forprofit company.

		• 4•	
А	bb	reviations	

565758

59

60

61 62 63

64

65

66 67

68 69 70

71

72

73

74

40	CSER	Clinical Sequencing Exploratory Research
11	CC	

- 41 CS carrier screening
- 42 CS-L carrier screening, large panel 43 CS-M carrier screening, medium panel
- 44 CS-S carrier screening, small panel
- 45 CT computed tomography
- 46 CTICU cardiothoracic intensive care unit
- 47 eMERGE Electronic Medical Records & Genomics EHR
- 48 EMR electronic medical record
- 49 ER emergency room
- 50 ICD International Classification of Diseases
- MRI magnetic resonance imaging
 MSHS Mount Sinai Health System
 NICU neonatal intensive care unit
 NPV negative predictive value
 PPV positive predictive value

Article Summary:

Algorithm using EMR data to identify children who have been diagnosed with a genetic disorder or present with illness with increased risk of genetic disorders.

What's known on this subject:

With over 7000 Mendelian disorders, identifying children with a specific rare genetic disorder diagnosis through structured EMR data is challenging given incompleteness of records, inaccurate medical diagnosis coding, as well as heterogeneity in clinical symptoms and procedures for specific disorders.

What this study adds:

We developed a digital phenotyping algorithm using electronic medical records (EMR) data to identify children aged 0-3 who have been diagnosed with genetic disorders or present with illness with an increased risk for genetic disorders from a mother-child cohort.

Author Contributions Statement Page

75

76

79

82

84

87

91

94

98

- Dr. Bryn Webb interpreted the data and results, carried out chart review, drafted the manuscript,
 and critically reviewed and revised the manuscript.
- Dr. Lisa Lau coordinated data collection, analyzed, and interpreted the data; drafted the manuscript, and critically reviewed and revised the manuscript.
- 83 Dr. Despina Tsevdos carried out chart review, drafted, reviewed, and revised the manuscript.
- Dr. Ryan Shewcraft analyzed the data, drafted the manuscript, reviewed, and revised the manuscript.
- Seungwoo Lee, Drs. David Corrigan, Lisong Shi, Jonathan Tyler, Shilong Li, Zichen Wang, Lisa Edelmann, and Gustavo Stolovitzky participated in acquisition of data, interpreted the data, participated in drafting the manscript, and revised the manuscript.
- 92 Dr. Rong Chen designed the study, collected, analyzed, and interpreted the data; critically reviewed and revised the manuscript.
- 95 Drs. Li Li and Eric Schadt conceptualized, designed, and supervised the study; collected the data, 96 interpreted the data and results, drafted the manuscript, critically reviewed and revised the 97 manuscript.
- All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Abstract

102 Objectives

101

106

115

122

127

- Develop a digital phenotyping algorithm (PheIndex) using electronic medical records (EMR)
- data to identify children aged 0-3 who have been diagnosed with genetic disorders or present
- with illness with an increased risk for genetic disorders from a mother-child cohort.
- 107 Methods
- We established 13 criteria for the algorithm where two metrics a quantified score and a
- 109 classification were derived. The criteria and the classification were validated by chart review
- from a pediatrician and clinical geneticist. To demonstrate the utility of our algorithm in real-
- world evidence applications, we examined the association between size of carrier screening
- panel (small/\le 4 genes [CS-S] vs large/\ge 100 genes [CS-L]) undertaken by mothers prior to
- delivery, and children classified as presenting with illness with an increased risk for genetic
- disorders by our algorithm.
- 116 Results
- The PheIndex algorithm identified 1,088 such children out of 93,154 live births and achieved
- 90% sensitivity, 97% specificity, and 94% accuracy by chart review. We found that children
- whose mothers received CS-L were less likely to be classified as presenting with illness with an
- increased risk for genetic disorders and a decreased need to have multiple specialist visits and
- multiple ER visits, compared to children whose mothers received CS-S.
- 123 Conclusions
- The PheIndex algorithm can help identify when a rare genetic disorder may be present, and has
- the potential to improve healthcare delivery by alerting providers to consider ordering a
- diagnostic genetic test and/or referring a patient to a medical geneticist or other specialists.

Introduction

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

The widespread adoption of electronic medical record (EMR) systems has the potential to enable large-scale population-based studies characterizing patients with rare disorders. While identifying genomic information from EMR systems would assist in identifying such patient populations, with groups from Clinical Sequencing Exploratory Research (CSER) and Electronic Medical Records & Genomics © (eMERGE) representing such efforts, they have noted that genetic information is most commonly stored in unstructured formats such as PDF files or in paragraphs of free text, making genetic testing results difficult to locate. 2,3 Additionally, CSER and eMERGE have not pursued a global approach to identifying patient populations with confirmed genetic disorders, or patients yet to be diagnosed with a genetic condition but rather whose medical records indicate that diagnostic genetic testing is warranted. Indeed, digital phenotyping studies using EMR data have largely focused on identifying populations with specific individual diseases, such as extracting patients with pediatric epilepsy, childhood obesity, or Noonan syndrome.⁴⁻⁷ When using EMR data to identify patient populations affected with rare genetic disorders, focusing on a specific rare genetic disorder diagnosis for any given patient is error-prone for many reasons. First, of 6519 rare disorders assessed, only 11% have International Classification of Disease 9 (ICD-9) codes and 21% have ICD-10 codes; some ICD codes are nonspecific, often with multiple phenotypes corresponding to a single ICD code.⁸ Furthermore, physicians and clinicians sometimes log certain ICD codes as they rule in or out a given condition, or when a condition is part of a differential diagnosis, yet still unconfirmed. Diagnosis codes may also be inaccurate or incomplete.9

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

Accordingly, algorithms that assess the risk of genetic disorders have the potential to improve healthcare delivery by assisting physicians and clinicians with clinical decision-making, including guiding when to order a diagnostic genetic test and/or refer a patient to a medical geneticist or other specialists may be indicated. Further, such algorithms could also be leveraged to identify rare genetic disorders patient populations to carry out cross-sectional and longitudinal epidemiological studies, assess healthcare utilization, and flag patients who may be considered for participation in specialized undiagnosed disease programs and precision medicine initiatives as underdiagnosis of rare genetic disorders is not uncommon. 10 As a collaborative, multidisciplinary team, we developed a digital phenotyping algorithm that used structured EMR data and assessed 13 criteria to identify patients from birth to 3 years of age who have been diagnosed with a rare genetic disorder or who are at high risk for such a diagnosis. We tested our algorithm using a real-world dataset comprised of 93,154 live births with children linked to mothers' medical records in a large academic health system. We validated the algorithm through blinded chart review by a pediatrician and a clinical geneticist. To demonstrate the real-world evidence application of our algorithm, we examined the health outcomes of children whose mothers received carrier screening; specifically, whether there was an association between children who were classified as presenting with illness with an increased risk for genetic disorders by our algorithm, and the size of the carrier screening panel received by the mothers of these children. To the best of our knowledge, we are the first to generate a digital phenotyping algorithm beyond using ICD codes to identify children presenting with illness with an increased risk for genetic disorders and employed this algorithm to assess healthcare outcomes in a large, diverse, pediatric population.

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

Methods Construction of mother-child cohort We obtained de-identified EMR data through June 30, 2020 from the Mount Sinai Health System (MSHS). In total, we identified 93,154 mother-child pairs delivered at MSHS hospitals, covering 68,893 mothers and 93,154 children. 11-13 The newborns in this cohort were born from 2007 to 2019, ensuring that all newborns had at minimum one year of follow-up (see also Supplemental Materials). This study was approved by the Mount Sinai institutional review board (IRB): IRB-20-01771. Digital phenotyping algorithm for rare genetic disorders The *PheIndex* (Phenotype Index) digital phenotyping algorithm was developed based on 13 criteria that may be present in children with a rare genetic disorder. These criteria are primarily based on healthcare utilization patterns such as hospital encounters, procedures, specialist visits, and laboratory test orders. Orders that were subsequently cancelled were not considered. Additional criteria that were included were diagnostic codes of developmental delay and metabolic disease, and death. Description of the criteria with the associated scores is listed in Table 1. PheIndex combines these criteria in two different ways: (1) "PheIndex Score", a quantified score indicating the severity of illness with a possible range between 0 and 24 generated by the sum of the score(s) associated with the criteria met by a child; and (2) "PheIndex Classification", a binary classification of those who present with illness with an increased risk for genetic disorders (*PheIndex Classification* positive) if the following conditions are met: (a) ≥ 2 major criteria, (b) ≥ 1 major criteria and ≥ 1 minor criteria, (c) ≥ 5 minor criteria, or

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

(d) deceased patient; or those who do not present illness with increased risk for genetic disorders (PheIndex Classification negative). Chart review verification of the PheIndex digital phenotyping For the blinded chart review, we selected 200 charts consisting of children who were PheIndex Classification positive (N=100) and PheIndex Classification negative (N=100). We ensured that the 100 children who were negative covered quantified scores from 0 to 6 (inclusive), and from 3 to 21 for 100 children who were positive, based on the distribution of the PheIndex Score. Available records for this review were from encounters dated 01/01/2005 to 06/30/2020. All criteria determinations were based on available medical records up until three years of age. The review by the pediatrician had two steps: 1) validate the accuracy of the values assigned to each of the 13 criteria for each patient; and 2) summarize diagnostic information from the patient charts. The pediatrician had access to additional delivery notes, progress notes, admission/discharge summaries, and imaging notes. Information on diagnoses available in the notes documented by the pediatrician was then used by a clinical geneticist to decide whether the child presented with illness with an increased risk for genetic disorders. The possible categories of determination were: 1) "Definitively/possibly has genetic disorder diagnosis", 2) "Does not have a genetic disorder", 3) "Unknown, insufficient information to make determination on whether a genetic disorder was related with illness." Statistical analysis Full details are described in Supplemental Materials.

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

Results Distribution of the 13 criteria in PheIndex Our cohort included 93,154 newborns linked to 68,893 mothers who delivered in the MSHS from 2007 to 2019, with clinical features collected to 2020 (Table 2). We first assessed the frequency of each of the 13 PheIndex digital phenotyping criteria in our cohort and summarized the number of children aged 0 to 3 years old that satisfied each of the 13 criteria (Table 3). The most common criteria were multiple ER visits (3,919; 4.22%), followed by developmental delay (3,159; 3.39%), and multiple visits to specialists (3,091; 3.32%). The least common criteria were metabolic disease diagnosis codes (82; 0.09%) and feeding support (132; 0.14%). Figure 1A and 1B demonstrate the expected temporal relationship for achieving each criterion. We generated a heatmap to show the number and percentage of patients who fell into different major and minor criteria combinations (Figure S1). The distribution for the total number of criteria for each child is given in Figure 1C. A large majority of patients (88.51%) did not meet any of the 13 criteria, and 98.55% met ≤2 criteria. We showed the distribution of PheIndex Classification – children who presented with illness with an increased risk for genetic disorders or not – stratified by the *PheIndex Score* (Figure 1D), as the *PheIndex Classification* depends on the specific combination of major and minor criteria for each patient. The majority of patients had a *PheIndex Score* ≤ 2 (97.23%), indicating that most children in our study population were not likely to have a rare genetic disorder. With our 13 criteria, the *PheIndex* Classification identified 1,088 children who were presenting with illness with an increased risk for genetic disorders out of 93,154 children (1.2%). Hospital utilization patterns are known to vary between pre-term and full-term infants, e.g. pre-term infants often have more prolonged NICU stays. To assess this, we computed the

243

244

245

246

247

248249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

similarity between all pairs of *PheIndex* criteria using the Jaccard index for each group (Figure 1E and 1F, Supplemental Materials). In the full-term cohort, heart surgeries and prolonged NICU stay had the highest Jaccard similarity of 0.44, in line with what we would expect to observe clinically. In the preterm cohort, prolonged NICU stay was not chosen to be a criterion because the majority of preterm infants have an extended NICU stay regardless of whether they have a rare genetic disorder or not. Validation of PheIndex: 13 Criteria and Overall Classification First, we evaluated the accuracy of the values that were extracted from the EMR and assigned to the 13 different criteria for each patient, by comparing *PheIndex*'s identification of each of the 13 criteria against a pediatrician's evaluation directly from the clinical notes for each patient, for a sample of 200 children (Table 4). The 200 children were sampled from those classified as presenting with illness with an increased risk for genetic disorders positive for a rare genetic condition (N=100) and those classified as negative (N=100). From this comparison, our digital phenotyping algorithm achieved an average accuracy of 94% across the 13 criteria. Accuracies were ≥90% for all criteria except for "prolonged NICU stays", which yielded an accuracy of 81%. Next, we compared the *PheIndex Classification* against the classifications made by a pediatrician/medical geneticist (Table 5). Among the 200 children reviewed, 12 patients did not have sufficient clinical information for the medical geneticist to assess whether a genetic disorder may be present. Ten of these 12 patients were born extremely prematurely (born before 28 gestational weeks), which led to uncertainties as to whether the criteria that were met was because of prematurity or because of an underlying genetic disorder (as determined by the medical geneticist). Therefore, these 12 patients were excluded from this performance evaluation.

267

268

269

270

271

272

273

274

275

276277

278

279

280

281

282

283

284

285

286

287

288

Among the 188 patients remaining (88 classified as positive by *PheIndex* and 100 classified as negative), 85 patients were deemed to be true positives (definitively or possibly has a rare genetic disorder by chart review, 90% sensitivity/recall) and 91 patients were deemed to be true negatives (does not have a genetic disorder, 97% specificity). Three patients who were classified as positive by *PheIndex* were not thought to have a genetic disorder (false positive), and 9 patients were thought to definitively or possibly have genetic disorders but were classified as having no genetic disorders by *PheIndex* (false negative), yielding a positive predictive value (PPV) of 97%, negative predictive value (NPV) of 91%, and 94% accuracy. If we considered the prevalence of rare genetic disorders to be 3-3.6% of all livebirths, ¹⁴ the adjusted PPV ranges from 48.1% to 48.3%. 15 PheIndex Scores by Carrier Screening Gene Panel Size We examined the association between the *PheIndex Score*, an indicator of disease severity, and the three panel sizes (CS-S, CS-M, and CS-L). We first identified that 3 *PheIndex* criteria (multiple inpatient hospital stays, genetic testing, and developmental delay) were enriched for infants whose mothers had performed only CS-S testing compared with CS-M and CS-L (Table 6). For patients with at least 1 year of follow-up, we observed that the overall PheIndex Scores were higher in CS-S (mean=0.70) compared to CS-M (mean=0.38, p<0.001) and CS-L (mean=0.57, p<0.001) (Figure 3A); and CS-S (mean=0.85) compared to CS-M (mean=0.47, p<0.001, Student's T-test) and CS-L (mean=0.70, p<0.001) for patients with at least 2 years of follow-up (Figure 3D). Comparison of time to onset for each criterion for CS-S and CS-L

To investigate the contributions of clinical factors to the *PheIndex* criteria and scores over time, we performed a sub-analysis between the CS-S and CS-L groups. We computed Kaplan-Meier survival curves for each of the 13 criteria for the CS-S and CS-L groups (Figure 4, Supplemental Figure 2) to examine the association of outcomes with time. We found that children in the CS-L cohort were less likely to see multiple specialists (p<0.001, Figure 4A), have multiple visits to the ER (p<0.001, Figure 4B), and less likely to undergo heart surgeries (p=0.06) or die early in childhood (p=0.058), compared to children in the CS-S cohort.

Regression Analysis

In the Cox proportional hazards model, we found that for children whose mothers were administered a CS-L panel, a 36% (p=0.005) reduction of being classified as presenting with illness with an increased risk for genetic disorders was estimated, compared to the children whose mothers ordered were administered a CS-S panel test (Supplemental Figure 4).

Discussion

Identifying pediatric patients across an entire population with or who possibly has a rare genetic disorder is critical for improving patient outcomes. We and others have attempted to identify patients with specific genetic disorders using EMR data, but have found that such a process is not straightforward, largely due to coding differences, unconfirmed diagnoses, variation in disease names and terminology, and inaccurate information represented in medical records. For most rare genetic disorders, it is difficult to identify patients with specific genetic disorders, given ICD codes are often nonspecific. Additionally, seeking to analyze individual diseases, even in EMR databases with millions of patients, would result in

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

underpowered studies given the low frequency of individual rare genetic disorders. However, by using a global metric as opposed to ones derived from specific individual diseases, we were able to identify a large cohort that provided for sufficient statistical power to assess the association of differently sized CS panels with risk of genetic disorders. In this study, we developed a novel, rule-based digital phenotyping algorithm (*PheIndex*) that utilizes 13 criteria to derive a *PheIndex Score* for children from birth to 3 years of age, in order to classify whether a child is presenting with an illness that may be a rare genetic disorder. Importantly, our score is an evaluation of overall health rather than the presence of specific features of individual diseases. To our knowledge, such an approach has not been developed previously. The criteria for the *PheIndex Score* include items that could be extracted from the EMR with a high degree of precision and accuracy. Our PheIndex Score may be utilized for various purposes, including its use as a clinical guide to shorten the diagnostic odyssey of hardto-diagnose patients, timely administration of therapeutics by facilitating more rapid diagnosis, and/or assessing clinical benefit of genetic testing, all of which help enable the practice of precision medicine in a way that may be more accessible to all. Chart review from clinical genetics experts, confirmed that our *PheIndex* algorithm has the following performance characteristics when the numbers of cases and controls are equal: precision of 97%, recall of 90%, and accuracy of 94%. To demonstrate the ability of our algorithm to identify an enriched set of patients at risk of harboring a rare genetic condition, we leveraged carrier screening results in mothers who delivered a baby in a large health system. We examined the association between a mother's carrier screening panel size and *PheIndex Score*. We found that CS-L was not only associated

with a lower overall *PheIndex Score*, but was also significantly associated with a decreased need

for a child having multiple specialist visits and multiple ER visits. In our sub-analysis using a cohort of mother-child pairs whose mother received CS-L or CS-S and with whom the child received at least two years of follow-up, we noted that those in the CS-L group reached the criteria of *multiple specialists* and *genetic diagnostic tests* earlier than those in the CS-S group. This result is notable as it supports that administration of a CS-L panel test may enable earlier diagnosis of genetic disorders in children. Alternatively, testing using a CS-L panel may increase awareness of parental carrier status, thus enabling prenatal diagnostic testing for a larger number of conditions. This increased awareness may also lead to early referral of children manifesting severe illness for rare genetic diagnostic testing and subsequent referrals to the appropriate specialists and potentially earlier treatment. Parental carrier status may also lead to earlier postnatal diagnostic genetic testing and thus confirmation of a particular genetic disorder.

Limitations

While our study population is likely representative of other large, diverse metropolitan areas, it may be less representative of smaller-sized cities and rural areas. Also, we provided an adjusted PPV of 48% based on an estimated prevalence of rare genetic disorders in the general population. However, precise estimates of rare genetic disorder prevalence are unavailable, and may also not reflect the PPV for the target population of our algorithm (i.e. children aged 0-3) due to differences in age of onset. Another potential limitation of our study is that we used only de-identified data available in structured EMR databases, and thus did not include all the information that would be available to physicians, such as clinical notes. However, despite not having access to all available clinical notes, our digital phenotype agreed with physician chart review 94% of the time (under conditions in which the number of cases and controls were

sampled to be the same), proving that our algorithm successfully identifies children possibly with rare genetic disorders. In the few occasions where there were discrepancies, this was typically due to incomplete documentation of orders, such as respiratory support and feeding support in PheIndex negative children that was uncovered in the notes during chart review. Thus, we believe that our digital phenotype will be more accurate using the *PheIndex* criteria extracted from notes in addition to structured EMR data. With respect to demonstrating the application of PheIndex across groups receiving comprehensive carrier screening and those receiving reduced or no carrier screening, the MSHS is unique in that beginning in 2016, CS-L was offered to all women considering pregnancy or already pregnant regardless of the mother's ability to pay or health insurance coverage. Notably, our cohort is comprised of linked mother-child pairs and thus does not directly assess the rate of mothers who chose not to continue pregnancies with an affected fetus; however, the improvement in health of children whose mothers received CS-L may be due to couples choosing to proceed with various reproductive health options such as in vitro fertilization (IVF), in order to reduce the chances of having a child affected with one of as many as 283 genetic conditions assessed in the CS-L panel described in our study. Additionally, mothers who chose to receive CS-L may be more likely to complete additional genetic testing via chorionic villus sampling or amniocentesis in the setting of advanced maternal age or family history of genetic disorders. Moreover, while we controlled for differential follow-up time and likely confounders, there may still be unmeasured confounding in the Cox regression model.

Conclusions

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

In summary, we utilized a comprehensive EMR to develop a novel digital phenotyping algorithm for identification of a pediatric population with a definitive or possible genetic

disorder. Our method utilizes a global approach as opposed to identifying patients in the EMR with each specific genetic disorder, which is fraught for misdiagnoses and error. In addition, our study is the first with adequate sample size and follow up to evaluate the health of children from birth to 3 years of age. Using a mother-child cohort that links children to mothers' genetic carrier screening status, we have identified that *PheIndex Scores* are lower at one or two years of follow-up in children whose mothers received CS-L relative to CS-S. We believe that our *PheIndex* algorithm will address an unmet need to identify children with rare genetic disorders and potentially help overcome well-known obstacles such as underdiagnosis and delayed diagnosis.²⁰

ACKNOWLEDGEMENTS

We would like to thank Drs. Mitchell K. Higashi and Paul Kruszka for reviewing the manuscript and Mount Sinai Data Warehouse for EMR data. We also thank the GeneDx IT team for infrastructural and computational support.

REFERENCES

- 1. Garcelon N, Burgun A, Salomon R, Neuraz A. Electronic health records for the diagnosis of rare diseases. *Kidney Int.* 2020;97(4):676-686. doi:10.1016/j.kint.2019.11.037
- 2. Shirts BH, Salama JS, Aronson SJ, et al. CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record. J Am Med Inform Assoc. Nov 2015;22(6):1231-42. doi:10.1093/jamia/ocv065
- 3. Williams MS, Taylor CO, Walton NA, et al. Genomic Information for Clinicians in the Electronic Health Record: Lessons Learned From the Clinical Genome Resource Project and the Electronic Medical Records and Genomics Network. Front Genet. 2019;10:1059. doi:10.3389/fgene.2019.01059
- 4. Yang Z, Shikany A, Ni Y, Zhang G, Weaver KN, Chen J. Using deep learning and electronic health records to detect Noonan syndrome in pediatric patients. Genet Med. Nov 2022;24(11):2329-2337. doi:10.1016/j.gim.2022.08.002
- 5. Cohen KB, Glass B, Greiner HM, et al. Methodological Issues in Predicting Pediatric Epilepsy Surgery Candidates Through Natural Language Processing and Machine Learning. Biomed Inform Insights. 2016;8:11-8. doi:10.4137/BII.S38308
- 6. Lingren T, Thaker V, Brady C, et al. Developing an Algorithm to Detect Early Childhood Obesity in Two Tertiary Pediatric Medical Centers. Appl Clin Inform. Jul 20 2016;7(3):693-706. doi:10.4338/ACI-2016-01-RA-0015
- 7. Wang Y, Wang L, Rastegar-Mojarad M, et al. Clinical information extraction applications: A literature review. J Biomed Inform. Jan 2018;77:34-49. doi:10.1016/j.jbi.2017.11.011
- 8. Fung KW, Richesson R, Bodenreider O. Coverage of rare disease names in standard terminologies and implications for patients, providers, and research. AMIA Annu Symp Proc. 2014;2014:564-72.
- 9. Horsky J, Drucker EA, Ramelson HZ. Accuracy and Completeness of Clinical Coding Using ICD-10 for Ambulatory Visits. AMIA Annu Symp Proc. 2017;2017;912-920.
- 10. Petrikin JE, Willig LK, Smith LD, Kingsmore SF. Rapid whole genome sequencing and precision neonatology. Semin Perinatol. Dec 2015;39(8):623-31. doi:10.1053/j.semperi.2015.09.009
- 11. Zheutlin AB, Vieira L, Shewcraft RA, et al. A comprehensive digital phenotype for postpartum hemorrhage. J Am Med Inform Assoc. Jan 12 2022;29(2):321-328. doi:10.1093/jamia/ocab181

- 12. Zheutlin AB, Vieira L, Shewcraft RA, et al. Improving postpartum hemorrhage risk prediction using longitudinal electronic medical records. J Am Med Inform Assoc. Jan 12 2022;29(2):296-305. doi:10.1093/jamia/ocab161
- 13. Li S, Wang Z, Vieira LA, et al. Improving preeclampsia risk prediction by modeling pregnancy trajectories from routinely collected electronic medical record data. NPJ Digit Med. Jun 6 2022;5(1):68. doi:10.1038/s41746-022-00612-x
- 14. Ferreira CR. The burden of rare diseases. Am J Med Genet A. 2019;179(6):885-892. doi:10.1002/ajmg.a.61124
- 15. Tenny S, Hoffman MR. Prevalence. [Updated 2022 May 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430867/ [Accessed 2022 Nov 12]
- 16. Miller KE, Hoyt R, Rust S, Doerschuk R, Huang Y, Lin SM. The Financial Impact of Genetic Diseases in a Pediatric Accountable Care Organization. *Front Public Health*. 2020;8:58. doi:10.3389/fpubh.2020.00058
- 17. Tisdale A, Cutillo CM, Nathan R, et al. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. *Orphanet J Rare Dis.* 2021;16(1):429. doi:10.1186/s13023-021-02061-3
- 18. Aymé S, Bellet B, Rath A. Rare diseases in ICD11: making rare diseases visible in health information systems through appropriate coding. *Orphanet J Rare Dis.* 2015;10:35. doi:10.1186/s13023-015-0251-8
- 19. Navarrete-Opazo AA, Singh M, Tisdale A, Cutillo CM, Garrison SR. Can you hear us now? The impact of health-care utilization by rare disease patients in the United States. *Genet Med*. 2021;23(11):2194-2201. doi:10.1038/s41436-021-01241-7
- 20. Zanello G, Chan CH, Pearce DA; IRDiRC Working Group. Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients. *Orphanet J Rare Dis.* 2022;17(1):181. doi:10.1186/s13023-022-02337-2

Figure Captions

Figure 1. Distribution of *PheIndex* critera of children in the cohort.

- (A,B) Cumulative distribution of time when patients first meet each of the 13 *PheIndex* criteria. Only patients that met each criterion within the three-year limit were included in each cumulative distribution. (A) is sorted by the percentage of patients meeting the criteria at 200 days (least number of patients at the top).
- (C) Bar graph showing the showing the number and percentage of patients with passing different numbers of *PheIndex* criteria.
- (D) Distribution of *PheIndex* scores for children within the mother-child cohort.
- (E,F) Clustered heatmap showing the Jaccard index between possible pairs of *PheIndex* criteria in the pre-term (E) and full-term (F) cohorts. The number and percentage of patients for each criterion are labeled.

Figure 2. Summary statistics of the genetic carrier screening status for newborns in the mother-child cohort.

(A) Top: Numbers of newborns whose mothers were tested with different genetic carrier screens arranged by years of birth (YOB).

Bottom: Percentages of newborns whose mothers were tested with different genetic carrier screens arranged by YOB.

(B) Histogram showing the distribution of genetic carrier tests dates (by month) relative to delivery (inset, weekly).

Figure 3. *PheIndex* Scores across the carrier screening (CS) testing cohort stratified by length of follow-up.

- (A) Average *PheIndex* score from the digital phenotype for all children with ≥ 1 year of follow-up in each CS testing cohort. Error bars show 95% confidence interval. *** denotes p<0.001.
- (B) Violin plot of *PheIndex* scores using the same categories as (A), but only including children labelled as "positive" from digital phenotype.
- (C) Percentage of children labelled as "positive" for each CS testing cohort. Error bars show 95% confidence interval. (D-F) Same as (A-C) but only including children with at least two years of follow-up.

Figure 4. Kaplan-Meier curves stratified by carrier screening panel size, Carrier screening, small panel / CS-S (blue) vs Carrier screening, large panel / CS-L (orange).

(A) Shows that children whose mothers received CS-S met the multiple specialist criterion in a greater proportion than those whose mothers received CS-L at three years of follow-up.

(B) Shows that children whose mothers received CS-S met the multiple ER visits criterion in a greater proportion than those whose mothers received CS-L at three years of follow-up. Shaded areas denote 95% confidence interval.

Figure 1




Figure 2




Figure 3






Figure 4





At risk

Events

Censored

Table 1: Description and scoring for the 13 PheIndex criteria

Description	Scoring
Prolonged stay in the neonatal intensive care unit (NICU) for term babies. Full-term newborns who were admitted to the NICU and stayed for \geq 4 days.	Major; score = 3
Prolonged or multiple hospitalizations after discharged from birth. Hospitalization is defined	
as inpatient stays with a duration ≥48 hours. We included hospital stays where the calculated	
gestational age is older than 35 weeks and exclude the first newborn encounter if earlier than	
35-week gestation. To meet this criterion, the patient must have either at least one prolonged	Major; score = 3
hospitalization (≥14 days) or at least two hospitalizations (≥48 hours duration) for full-term	
or ≥3 hospitalizations (≥48 hours) for pre-term babies.	
Visits or consults with multiple specialists other than general pediatricians.	
Twenty types of specialists were considered: Medical Genetics, Neurosurgery, Pediatric	
Allergy and Immunology, Pediatric Cardiology, Pediatric Dermatology, Pediatric	
Endocrinology, Pediatric GI/Pediatric Liver, Pediatric Hematology/Oncology, Pediatric	
Nephrology, Pediatric Neurology, Pediatric Ophthalmology, Pediatric Orthopedics, Pediatric	
Otolaryngology, Pediatric Pulmonology, Pediatric Rheumatology, Pediatric Surgery,	Minor; score = 1
Pediatric Urology, Transplant, Plastic Surgery. We counted the types of specialists each patient visited or consulted with and not the number of individual specialist visits. Preterm	
babies with ≥ 4 types of specialists or full-term babies with ≥ 3 types of specialists meet this	
criterion. We excluded Pediatric Infectious Disease specialty visits as infections in general	
are primarily due to environmental and non-genetic etiologies, and our aim was to identify a	
patient population enriched for children with genetic disorders.	
Multiple emergency room (ER) visits.	3.61
Full-term babies with \geq 5 ER visits or preterm babies with \geq 7 ER visits meet this criterion.	Minor; score = 1
Feeding support (Gastrostomy tube).	
Patients who required feeding support were identified using ICD codes (Supplemental Table	Minor; score = 2
2A) and procedures with description of "nasogastric", "gastrostomy" and "feed", or	Willion, Score – 2
"gastrostomy" and "tube" in the procedure name.	
Respiratory support (tracheostomy and mechanical ventilation outside of surgery).	
We used tracheostomy and ventilation (including CPAP) identified by procedure codes and	Minor; score = 2
diagnosis codes. If a surgical procedure was performed, the ventilatory support was required	
to be performed either 1 day before or 5 days after surgeries to be able to meet this criterion. Imaging.	
We included patients that received computed tomography (CT) or magnetic resonance	
imaging (MRI) with completed encounter order status or preliminary/final results available	Minor; $score = 1$
from radiological exams.	
Genetic diagnostic tests.	
We included patients who received genetic diagnostic tests such as gene sequencing or array) //: 1
comparative genomic hybridization regardless of test results. The records of genetic	Minor; score = 1
diagnostic tests were retrieved from procedure codes and labs.	
Metabolic diagnostic tests.	
We included patients who received metabolic tests such as plasma amino acids panel or urine	Minor; score = 1
organic acids panel, regardless of test results. The records of metabolic diagnostic tests were	1,111101, 50010
retrieved from procedure codes and labs.	
In-hospital death.	Main and 2
Death information was retrieved from discharge location/disposition (expired, to funeral	Major; score = 3
home/morgue or organ harvest) from encounter records. Developmental delay.	
Patients with developmental delay were identified by either a specialist visit with a	
developmental pediatrician or at least two occurrences of related ICD codes (Supplemental	Minor; score = 1
Table 2B)	
Diagnosis codes corresponding to metabolic diseases with ≥ 2 encounters, (major, score=3).	Maine
We included patients with ICD codes for metabolic diseases (Supplemental Table 2C).	Major; score = 3

Description	Scoring
Heart surgeries, (major, score=3).	
Newborns that received heart surgeries were identified by encounters related to cardiothoracic surgeries or cardiothoracic intensive care unit (CTICU).	Major; score = 3

Table 2: Demographic information of cohorts by carrier screening status.

		CS-S	CS-M	CS-L	All	p-value	Test
	#	9786	7130	14264	93154		
	Delivery age, median [Q1,Q3] Race, n (%)	32.9 [29.4,36.2]	34.3 [31.5,37.2]	33.7 [30.6,36.7]	32.5 [28.2,36.1]	<0.001	Kruskal- Wallis
	, , ,						
	African-American/Black	1475 (15.1)	142 (2.0)	1609 (11.3)	9423 (10.1)		
Demographics &	Asian	1283 (13.1)	238 (3.3)	1437 (10.1)	6911 (7.4)		
socioeconomics of mothers	Caucasian/White	3538 (36.2)	6167 (86.5)	7002 (49.1)	52667 (56.5)		
of mothers	Hispanic/Latino	2422 (24.7)	226 (3.2)	2180 (15.3)	15543 (16.7)	<0.001	Chi- squared
	Native American	34 (0.3)	10 (0.1)	39 (0.3)	201 (0.2)		
	Other	820 (8.4)	225 (3.2)	1207 (8.5)	5747 (6.2)		
	Unknown	214 (2.2)	122 (1.7)	790 (5.5)	2662 (2.9)		
	Mother on Medicaid, n (%)	2821 (28.8)	229 (3.2)	3258 (22.8)	29219 (31.4)	< 0.001	Chi- squared
Health Insurance	Child on Medicaid, n	2461 (25.1)	105 (1.5)	2381 (16.7)	27392 (29.4)	< 0.001	Chi- squared
	Child switched to Medicaid, n (%)	25 (0.3)	7 (0.1)	28 (0.2)	154 (0.2)	0.07	Chi- squared
	Year of birth, median [Q1,Q3]	2015 [2013,2016]	2015 [2013,2017]	2018 [2017,2019]	2015 [2011,2017]	< 0.001	Kruskal- Wallis
	Pre-term birth, n (%)	1299 (13.3)	844 (11.8)	1671 (11.7)	11676 (12.5)	0.004	Chi-
Birth of children	Birth facility, n (%)					< 0.001	squared
Dirth of Children	Mount Sinai Hospital	8370 (85.5)	6518 (91.4)	9011 (63.2)	79350 (85.2)		
	Mount Sinai West	858 (8.8)	262 (3.7)	1934 (13.6)	5916 (6.4)	< 0.001	Chi- squared
	Other	558 (5.7)	350 (4.9)	3319 (23.3)	7888 (8.5)		Squared
Record completeness	latest follow-up age (days), median [Q1,Q3]	17.0 [0.0,713.0]	0.0 [0.0,191.2]	4.0 [0.0,401.0]	16.0 [0.0,596.0]	< 0.001	Kruskal- Wallis
	# of encounters, median [Q1,Q3]	2.00 [1.00,16.00]	1.00 [1.00,2.00]	2.00 [1.00,12.00]	2.00 [1.00,6.00]	< 0.001	Kruskal- Wallis

Note than p-value indicates difference between all carrier screening groups.

Table 3: Number of children passing each individual *PheIndex* criteria.

PhenoIndex Criteria	n (%)
multiple ER visits	3919 (4.2)
developmental delay	3159 (3.4)
multiple specialists	3091 (3.3)
respiratory support	2838 (3.0)
imaging	1113 (1.2)
genetic tests	704 (0.8)
prolonged in-patient stays	500 (0.5)
metabolic tests	448 (0.5)
death	371 (0.4)
heart surgeries	304 (0.3)
prolonged NICU stay	279 (0.3)
feeding support	132 (0.1)
metabolic ICD codes	82 (0.1)

Table 4: Accuracy of digital phenotype algorithm compared to chart review for individual *PheIndex* criteria.

PhenoIndex Criteria	Accuracy
prolonged NICU stay	81%
prolonged in-patient stays	98%
multiple ER visits	94%
multiple specialists	93%
feeding support	96%
respiratory support	90%
imaging	97%
genetic tests	96%
metabolic tests	96%
death	98%
metabolic ICD codes	97%
developmental delay	93%
heart surgeries	97%

Table 5: Performance of *PheIndex* Classification against chart review.

		Clinical geneticist classification						
lex tion		Does not have genetic	Definitively or	Unknown	Total			
PhenoIndex Classification		disease	possibly has	(insufficient				
ific			genetic disease	information)				
PhenoInc	Negative	91 (True Negative)	9 (False Negative)	0	100			
	Positive	3 (False positive)	85 (True Positive)	12	100			
	Total	94	94	12	200			

Table 6: Number of children passing each individual *PheIndex* criteria split by carrier screen testing status.

	CS-S	CS-M	CS-L	All	P-Value	Test
#	9786	7130	14264	93154		
multiple ER visits, n (%)	623 (6.4)	25 (0.4)	424 (3.0)	3919 (4.2)	< 0.001	Chi-squared
developmental delay, n (%)	515 (5.3)	138 (1.9)	522 (3.7)	3159 (3.4)	< 0.001	Chi-squared
multiple specialists, n (%)	497 (5.1)	121 (1.7)	431 (3.0)	3091 (3.3)	< 0.001	Chi-squared
respiratory support, n (%)	348 (3.6)	201 (2.8)	665 (4.7)	2838 (3.0)	< 0.001	Chi-squared
imaging, n (%)	132 (1.3)	43 (0.6)	162 (1.1)	1113 (1.2)	< 0.001	Chi-squared
genetic tests, n (%)	75 (0.8)	31 (0.4)	95 (0.7)	704 (0.8)	0.03	Chi-squared
prolonged in-patient stays, n (%)	51 (0.5)	15 (0.2)	45 (0.3)	500 (0.5)	0.002	Chi-squared
metabolic tests, n (%)	49 (0.5)	26 (0.4)	69 (0.5)	448 (0.5)	0.38	Chi-squared
death, n (%)	44 (0.4)	10 (0.1)	41 (0.3)	371 (0.4)	0.001	Chi-squared
heart surgeries, n (%)	23 (0.2)	7 (0.1)	17 (0.1)	304 (0.3)	0.03	Chi-squared
prolonged NICU stay, n (%)	24 (0.2)	9 (0.1)	27 (0.2)	279 (0.3)	0.22	Chi-squared
feeding support, n (%)	13 (0.1)	3 (0.0)	13 (0.1)	132 (0.1)	0.16	Chi-squared
metabolic ICD codes, n (%)	3 (0.0)	4 (0.1)	11 (0.1)	82 (0.1)	0.38	Chi-squared
# of PheIndex criteria, mean (SD)	0.24 (0.69)	0.09 (0.41)	0.18 (0.59)	0.18 (0.63)	< 0.001	One-way ANOVA
PheIndex Score, mean (SD)	0.31 (0.98)	0.13 (0.62)	0.24 (0.87)	0.25 (0.97)	< 0.001	One-way ANOVA